Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2016 Earnings Results

Arrowhead Pharmaceuticals Misses on Revenue, Stock Down 0.69%

Arrowhead Pharmaceuticals reported a loss per share of $0.35, which was slightly better than expected, but no revenue figures were provided. The stock reacted negatively, declining by 0.69%. Investors may be concerned about the lack of revenue information and future guidance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.35	N/A	+4.63%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

Arrowhead Pharmaceuticals Misses on Revenue, Stock Down 0.69%

Key numbers

Management commentary

Arrowhead Pharmaceuticals, Inc.

More earnings this week

Arrowhead Pharmaceuticals Misses on Revenue, Stock Down 0.69%

Key numbers

Management commentary